Lipidomics

• Sapient , a biomarker discovery organization providing bespoke services for multi-omics data generation and analysis, has announced the roll-out of its high throughput discovery proteomics services, enabling measure of thousands of proteins in blood and tissue across diverse biological pathways.
• This offering further extends Sapient’s capabilities for dynamic biomarker discovery, utilizing its state-of-the-art mass spectrometry -based platform, which also powers its discovery metabolomics and lipidomics approaches.
• “We are particularly excited to extend Sapient’s offerings to include discovery proteomics,” said Jeramie Watrous, PhD, Co-Founder and Head of Analytical R&D at Sapient.
• More information on Sapient’s high throughput discovery proteomics can be found at: https://sapient.bio/discovery-proteomics-services/

• Both horses and people with endocrine disorders like Type 2 diabetes can suffer multiple types of musculoskeletal disorders.
• For example, horses with pituitary pars intermedia dysfunction – similar to Cushing’s disease in people – suffer from tendon and ligament degeneration.

Human and horse endocrine systems

• Some endocrine disorders change how your body produces and releases hormones and can lead to osteoporosis, arthritis, ligament injury and other orthopedic diseases.
• In fact, approximately 20% of horses and over 34% of people in the U.S. are affected by endocrine disorders such as metabolic syndrome.
• For both species, the degree to which endocrine disorders are connected to obesity and its associated negative health effects is complex.
• As mammals, horses and people share similar anatomy and endocrine physiology, and researchers have noted their parallel genetic links between obesity and metabolic disease.

Research to note

• Because of the similarities between people and horses, research on diagnostics and treatments for metabolic conditions could provide health benefits to both species.
• These drugs alter the kidneys’ ability to absorb sugar from urine such that the body eliminates some of the glucose it would normally absorb.
• This greatly reduces blood insulin spikes, which can help prevent obesity, metabolic syndrome and cardiovascular disease in both horses and people.

Expanding precision medicine

• Instead of the standard one-size-fits-all protocol, precision medicine uses information from a person’s genes, environment and medical history to create a customized treatment plan.
• In horses, precision medicine currently focuses on DNA-based diagnostic tests to inform exercise regimens, treatment and breeding decisions.
• Within precision medicine, doctors aim to get a full-picture view of an individual and their metabolic health by using multiomic analysis.

• Agilent Technologies Inc. (NYSE: A) announced today that the recipient of the 2023 Darlene Solomon Award is Kathryn Wolhuter, Ph.D., a senior postdoctoral researcher studying coronary heart disease at the Victor Chang Cardiac Research Institute in Sydney, Australia.
• The award was presented at the iSLS11 - 11th International Singapore Lipid Symposium held March 21–23 at the National University of Singapore.
• “I am honored to receive the Darlene Solomon Award from Agilent and FeMS, which has enabled me to attend the iSLS11 in Singapore and exchange ideas with female leaders in the field,” said Dr. Kathryn Wolhuter.
• “This award will further my ambition of promoting women within mass spectrometry by gaining exposure at an international level.

• Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's common stock on The Nasdaq Capital Market LLC under the trading symbol, "HEPA."
• The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share under Rule 5550(a)(2) on June 3, 2022, and was given until November 30, 2022, to regain compliance.
• The Company will continue to monitor its bid price of its common stock.
• If the Company does not meet the minimum bid requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that it's common stock will be subjected to delisting.